|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face 显示文摘 | Fata F O'Reilly E Ilson D | 1999 | Cancer1999，86，10： | 1 |
| 2 | Analysis of survival with modified docetaxel,cisplatin,fluorouracil(mDCF),and bevacizumab(BEV)in patients with metastatic gastroesophageal(GE)adenocarcinoma:results of a phase II clinical trial显示文摘 | Kelsen D Jhawer M Ilson D | 2009 | J Clin Oncol2009，，： | 1 |
| 3 | Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face 显示文摘 | Fata F O' Reilly E Ilson D | 1999 | Cancer1999，86，10： | 1 |
| 4 | Analysis of survival with modified docetaxel,cisplatin,fluorouracil(mDCF),and bevacizumab(BEV) in patients with metastatic gastroesophageal(GE)adenocarcinoma:Results of a phase Ⅱ clinical trial显示文摘 | Kelsen D Jhawer M Ilson D | 2009 | ASCO Meeting2009，27，： | 1 |
| 5 | Pacli*axel given by a weekly 1-h infusion in advanced esophageal cancer显示文摘 | Ilson D H Wadleigh R G Leichman L P | 2007 | AnnOncol2007，18，7： | 1 |
| 6 | A dose-response study to assess the renal hemodynamic,vascular and hormonal effects of eprosartan:an angiotensin Ⅱ AT1 receptor antagonist insodium-replete healthy men显示文摘 | Boike S C Martin D E | 1998 | Clin Pharmacol Ther1998，63，4： | 1 |
| 7 | A Multi - centerPhase Ⅱ study of Irinotecan ( CPT), Cisplatin ( CIS ), and Bevacizumab(BEV) in patients with unresectable ormeta- static gastric or gas troesophageal junction (GEJ) adenocarcinoma 显示文摘 | Shah M A Ilson D Ramanathan R K | 2005 | Proc Am Soc ClinOncol2005，24，： | 1 |
| 8 | Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer显示文摘 | ILSON D H BAINS M KELSEN D P | 2003 | J Clin Oncol2003，21，15： | 1 |
| 9 | A multicenter phase Ⅱ study of irinotecan (CPT),cisplatin (CIS),and bevacizumab (BEV) in patients with unresectable or metastable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma 显示文摘 | Shah MA Ilson D Ramanathan RK | 2005 | J Clin Onco:2005 ASCO Annual Meeting Proceedings2005，23，16： | 1 |
| 10 | A muhicenter phase Ⅱ study of irinotecan (CPT),cisplatin (CIS),and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenecarcinoma显示文摘 | Shah M A Ilson D Ramanathan R K | 2005 | J Clin Oncol2005，23，16： | 1 |
| 11 | Phase Ⅰ study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors显示文摘 | Schwartz GK O'Reilly E Ilson D | 2002 | J Clin Oncol2002，20，8： | 1 |
| 12 | Muhicenter Phase Ⅱ study of irinotecan,cisplatin,and bevacizumab in patients with metastatic gastric or gastroesophagealjunction adenocarcinoma显示文摘 | shah M A Bamanathan R K Ilson D | 2006 | J Clin Oncol2006，24，33： | 1 |
| 13 | Oesophageal cancer: new developments in systemictherapy显示文摘 | Ilson D H | 2003 | Cancer Treat Rev2003，29，6： | 1 |
| 14 | Paclitaxel given bya weekly 1-h infusion in advanced esophageal cancer显示文摘 | Ilson D H Wadleigh R G Leichman L P | 2007 | Ann Oncol2007，18，5： | 1 |
| 15 | A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus 显示文摘 | Ilson DH Kelsen D Shah M | 2011 | Cancer2011，117，7： | 1 |
| 16 | Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumah-based therapy 显示文摘 | Shah MA Ilson D Kelsen DP | 2005 | J Clin Oncol2005，23，11： | 1 |
| 17 | Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face 显示文摘 | Fata F O'Reiny E Ilson D | 1999 | Cancer1999，86，10： | 1 |
| 18 | A phase 2 trial of erlo-tinib in patients with previously treated squamous cell and adeno-carcinoma of the esophagus 显示文摘 | ILSON D H KELSEN D SHAH M | 2011 | Cancer2011，117，7： | 1 |
| 19 | Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase I1 clinical trial显示文摘 | Kelsen D Jhawer M Ilson D | 2009 | J Clin Oncol2009，27，15： | 1 |
| 20 | Phase II study of the eyclin- dependent kinase inhibitor flavopifidol administered to patients with advanced gastric carcinoma显示文摘 | Schwartz GK Ilson D Saltz L | 2001 | J Clin Oncol2001，19，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员